JP2024504162A5 - - Google Patents
Info
- Publication number
- JP2024504162A5 JP2024504162A5 JP2023544485A JP2023544485A JP2024504162A5 JP 2024504162 A5 JP2024504162 A5 JP 2024504162A5 JP 2023544485 A JP2023544485 A JP 2023544485A JP 2023544485 A JP2023544485 A JP 2023544485A JP 2024504162 A5 JP2024504162 A5 JP 2024504162A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding portion
- bispecific car
- domain
- epc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140752P | 2021-01-22 | 2021-01-22 | |
| US63/140,752 | 2021-01-22 | ||
| PCT/US2022/013231 WO2022159653A2 (en) | 2021-01-22 | 2022-01-21 | Bispecific chimeric antigen receptors binding to cd19 and cd22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504162A JP2024504162A (ja) | 2024-01-30 |
| JP2024504162A5 true JP2024504162A5 (enExample) | 2025-01-28 |
Family
ID=82549829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544485A Pending JP2024504162A (ja) | 2021-01-22 | 2022-01-21 | Ｃｄ１９及びｃｄ２２に結合する二重特異性キメラ抗原受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082402A1 (enExample) |
| EP (1) | EP4281470A4 (enExample) |
| JP (1) | JP2024504162A (enExample) |
| KR (1) | KR20230137948A (enExample) |
| CN (1) | CN117062844A (enExample) |
| AU (1) | AU2022209703A1 (enExample) |
| CA (1) | CA3208935A1 (enExample) |
| IL (1) | IL304554A (enExample) |
| WO (1) | WO2022159653A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220050182A (ko) * | 2019-08-21 | 2022-04-22 | 엘피스 바이오파마슈티컬즈 | 항-cd22 항체 및 그의 용도 |
| US20260176354A1 (en) * | 2022-10-31 | 2026-06-25 | The Asan Foundation | Antibody binding to cd22, and bispecific antibody, chimeric antigen receptor and antibody-drug conjugate comprising same, and use thereof |
| CN116462770B (zh) * | 2023-04-18 | 2024-03-08 | 科弈(浙江)药业科技有限公司 | Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用 |
| KR20250174161A (ko) * | 2024-06-04 | 2025-12-12 | 한국과학기술연구원 | 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015340056A1 (en) * | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| TWI717375B (zh) * | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| WO2020069184A2 (en) * | 2018-09-26 | 2020-04-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
| JP2022531113A (ja) * | 2019-04-30 | 2022-07-06 | ギガジェン，インコーポレイティッド | 組換えポリクローナルタンパク質およびその使用方法 |
| AU2020331963A1 (en) * | 2019-08-19 | 2022-03-03 | Elpis Biopharmaceuticals | Anti-CD19 antibodies and uses thereof |
| KR20220050182A (ko) * | 2019-08-21 | 2022-04-22 | 엘피스 바이오파마슈티컬즈 | 항-cd22 항체 및 그의 용도 |
-
2022
- 2022-01-21 AU AU2022209703A patent/AU2022209703A1/en not_active Abandoned
- 2022-01-21 CA CA3208935A patent/CA3208935A1/en active Pending
- 2022-01-21 JP JP2023544485A patent/JP2024504162A/ja active Pending
- 2022-01-21 WO PCT/US2022/013231 patent/WO2022159653A2/en not_active Ceased
- 2022-01-21 EP EP22743215.0A patent/EP4281470A4/en active Pending
- 2022-01-21 CN CN202280021455.4A patent/CN117062844A/zh active Pending
- 2022-01-21 US US18/262,496 patent/US20240082402A1/en active Pending
- 2022-01-21 KR KR1020237028465A patent/KR20230137948A/ko active Pending
-
2023
- 2023-07-18 IL IL304554A patent/IL304554A/en unknown